Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.52 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 12/20 | 0.51 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151712 | 0.96 | ESR1 (0.51) | EDNRBEDNRAESR1MEN1KMT2A | |
| SCHEMBL4165406 | 0.95 | ESR1 (0.52) | EDNRBEDNRAESR1MEN1KMT2A | |
| SCHEMBL4167949 | 0.95 | ESR1 (0.52) | ESR1GRIK2MEN1KMT2APLA2G2A | |
| SCHEMBL4144091 | 0.93 | ESR1 (0.51) | ESR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4155886 | 0.92 | ESR1 (0.51) | EDNRBEDNRAESR1MEN1KMT2A | |
| SCHEMBL12939116 | 0.91 | ESR1 (0.49) | ESR1 | |
| SCHEMBL4160105 | 0.91 | ESR1 (0.60) | ESR1GRIK2GRIK1MEN1KMT2A | |
| SCHEMBL7837415 | 0.91 | EDNRB (0.45) | EDNRBEDNRAESR1MEN1KMT2A | |
| SCHEMBL4155561 | 0.91 | ESR1 (0.53) | ESR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6796561 | 0.90 | ESR1 (0.51) | EDNRBEDNRAESR1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8815934-B2 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| US-7449455-B2 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080021017-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2008-01-24 | — | — | US | disclosed |
| US-7247624-B2 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070142361-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations | WYETH (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070135396-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135397-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-6479535-B1 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations | WYETH | 2002-11-12 | — | — | US | disclosed |
| US-6326367-B1 | THERAPY FOR OVARIAN CANCER | AMERICAN HOME PRODUCTS CORPORATION | 2001-12-04 | — | — | US | disclosed |
| EP-0802183-B1 | Estrogenic agents | AMERICAN HOME PROD (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291451-B1 | USEFUL IN THE TREATMENT OR INHIBITION OF BREAST CANCER. | AMERICAN HOME PRODUCTS CORPORATION | 2001-09-18 | — | — | US | disclosed |
| US-20010021719-A1 | 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents | WYETH | 2001-09-13 | — | — | US | disclosed |
| US-6232307-B1 | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS USEFUL AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6225308-B1 | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS WHICH ARE USEFUL AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-6127404-A | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)INDOLE COMPOUNDS USEFUL AS ESTROGEN AGONISTS/ANTAGONISTS; OSTEOPOROSIS; ANTICHOLESTEROL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021719-A1 | 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents | ESR1, ESR2, GPER1 | EDNRB 216/4885EDNRA 88/4885ESR1 1/4885 |
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | EDNRB 60/4885EDNRA 45/4885ESR1 2/4885 |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | EDNRB 60/4885EDNRA 45/4885ESR1 2/4885 |
| US-20070135397-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | ESR2, ESR1, CYP19A1 | EDNRB 60/4885EDNRA 45/4885ESR1 2/4885 |
| US-20070135396-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | ESR2, ESR1, CYP19A1 | EDNRB 60/4885EDNRA 45/4885ESR1 2/4885 |
| US-20070142361-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations | ESR1, ESR2, CYP19A1 | EDNRB 60/4885EDNRA 40/4885ESR1 1/4885 |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | BRCA1, ESR2, PKD2 | EDNRB 794/4885EDNRA 809/4885ESR1 5/4885 |
| US-20080021017-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | BRCA1, PKD2, CYP19A1 | EDNRB 583/4885EDNRA 696/4885ESR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.